InstalabLoading...
InstalabLoading...
Some people spend years with worsening back pain and stiffness before anyone thinks to check whether their genes are part of the problem. HLA-B27 (Human Leukocyte Antigen B27) is one of those genetic clues that can change everything about how you and your doctors understand what is happening in your body. If you carry this gene variant and you have been dealing with back pain that started before age 45, improves with movement but not rest, and comes with prolonged morning stiffness, this test can help explain why.
Unlike most blood tests, this is not a number that goes up or down. HLA-B27 DNA typing is a one-time genetic test that tells you whether you carry this immune system variant. The result is either positive (you have it) or negative (you do not). About 6% of the U.S. population carries HLA-B27, and while most carriers never develop disease, those who do can benefit enormously from early recognition.
HLA-B27 is a protein that sits on the surface of your immune cells. Its normal job is to act as a display case: it picks up small fragments of proteins from inside the cell and presents them on the cell surface so that immune cells called CD8+ T cells can inspect them. This is how your immune system spots cells that have been infected by viruses or have turned cancerous. The fragments that do not belong get flagged, and the immune system attacks.
The HLA-B27 variant is one of thousands of versions of this display protein encoded by genes on chromosome 6. What makes it unusual is a structural quirk: an unpaired chemical hook (a cysteine residue at position 67) that lets HLA-B27 molecules stick together in pairs on the cell surface. Most other versions of this protein cannot do that. This abnormal pairing appears to set off a chain of inflammatory events that, in susceptible people, can lead to serious disease.
Over 200 subtypes of HLA-B27 have been identified. Not all carry the same risk. Subtypes B27:05, B27:02, B27:04, and B27:07 are strongly linked to disease. Two subtypes, B27:06 (common in Southeast Asian populations) and B27:09 (found in southern Italian and Sardinian populations), are not associated with spondyloarthritis despite being detected as "HLA-B27 positive" on standard tests.
The strongest disease association for HLA-B27 is with a group of inflammatory conditions called spondyloarthropathies, particularly ankylosing spondylitis and axial spondyloarthritis. These conditions cause chronic inflammation in the spine and sacroiliac joints (the joints connecting your spine to your pelvis), and over time can lead to permanent spinal fusion. Between 74% and 89% of people with these conditions carry HLA-B27, and the odds ratio exceeds 50, making it one of the strongest known gene-disease associations in all of medicine.
The absolute risk, however, is much lower than those numbers might suggest. Only about 2% to 10% of people who carry HLA-B27 ever develop spondyloarthritis. That risk increases substantially if you also have a first-degree relative (a parent or sibling) with ankylosing spondylitis. In a prospective study of seemingly healthy first-degree relatives of HLA-B27 positive ankylosing spondylitis patients aged 18 to 40, one-third already met classification criteria for spondyloarthritis, and 20% showed bone marrow swelling on MRI despite minimal symptoms.
Three main theories explain how HLA-B27 triggers inflammation. First, the protein may present fragments of your own tissue that look similar to fragments from bacteria, confusing the immune system into attacking healthy joints and spine tissue. Second, HLA-B27 has a tendency to misfold inside cells, triggering a stress response that ramps up production of inflammatory signaling molecules (particularly IL-23 and IL-17). Third, those abnormal HLA-B27 pairs on cell surfaces interact with receptors on immune cells, activating inflammatory pathways in multiple immune cell types.
HLA-B27 is not only about back pain. The gene variant is also associated with reactive arthritis (joint inflammation triggered by bacterial infections such as Chlamydia or gut bacteria), psoriatic arthritis (inflammatory arthritis in people with the skin condition psoriasis), and enteropathic arthritis (joint inflammation linked to inflammatory bowel diseases like Crohn's disease or ulcerative colitis).
Acute anterior uveitis, a painful inflammation of the front part of the eye, is another common association. This condition occurs in roughly 25% to 45% of people with axial spondyloarthritis. Among ophthalmology patients tested for HLA-B27, positivity rates of about 15% have been reported. Recurrent uveitis episodes, particularly in younger adults, are a strong signal to consider HLA-B27 testing.
A less well-known connection exists between HLA-B27 and certain heart problems. In case-control studies, HLA-B27 was found in 67% to 88% of male patients who had both aortic regurgitation (a leaky aortic valve) and severe electrical conduction problems in the heart, compared to 6% to 8% in the general population. This specific combination of heart findings is uncommon, but its strong association with HLA-B27 means that men diagnosed with both conditions should consider testing.
A national study of 32,630 U.S. veterans who had HLA-B27 testing found that HLA-B27 positivity was associated with a 15% increase in all-cause mortality over a mean follow-up of 4.6 years, after adjusting for age, sex, race, and inflammatory conditions. The association was strongest among veterans who also had spondyloarthritis, where the risk was 35% higher. In those without spondyloarthritis, the association did not reach statistical significance. This was a clinically selected population (people who had a reason to be tested), not a general population sample, so these numbers should be interpreted cautiously.
HLA-B27 testing has a sensitivity of about 50% and a specificity of 90% for axial spondyloarthritis. In practical terms, the test catches about half of all cases (some people with the disease are HLA-B27 negative), and about 90% of the time a negative result correctly identifies someone without the disease. The positive likelihood ratio is approximately 3.1, which is lower than doctors historically assumed.
This means HLA-B27 is not a diagnostic test on its own. A positive result does not mean you have spondyloarthritis, and a negative result does not rule it out. The test is most powerful when combined with clinical features (inflammatory back pain, enthesitis, uveitis, family history) and imaging (sacroiliac joint X-rays or MRI). MRI can detect bone marrow swelling and active inflammation years before X-ray changes appear, though bone marrow edema on MRI is also seen in up to 35% of healthy runners and 23% of people with ordinary back pain.
HLA-B27 prevalence varies by ethnicity. Roughly 8% of white populations carry the variant, compared to about 2% of African Americans. Specific subtypes cluster in different ethnic groups: B27:05 is most common worldwide and in white populations, B27:04 predominates in East Asian populations, B27:02 in Mediterranean populations, and B27:07 in South Asian and Middle Eastern groups.
A large French population study found that HLA-B27 increased the risk of spondyloarthritis 39-fold compared to people without the variant. Even so, the absolute prevalence of spondyloarthritis was only 0.43%, meaning approximately 94% of HLA-B27 carriers in the general population never develop the disease.
There are two main ways labs test for HLA-B27, and the method used affects accuracy. Older antibody-based methods (flow cytometry) identify the protein on cell surfaces. These have the highest error rate: 5.33% in proficiency testing by the College of American Pathologists. Antibody cross-reactivity can produce ambiguous results in about 3% of samples, and some patients with ankylosing spondylitis show surface antigen masking that can cause false negatives.
DNA-based molecular methods (PCR or sequencing) are more accurate. Sequence-specific methods have achieved 0% error rates in proficiency testing, and real-time PCR shows 100% concordance with reference genotyping when properly set up. However, one simpler DNA approach using a single genetic marker (SNP rs4349859) has only 78.6% sensitivity, missing about one in five true carriers. If your result came from flow cytometry and was borderline or unexpected, confirming with a molecular method is reasonable.
Because HLA-B27 is a genetic marker encoded in your DNA, the result does not change over your lifetime. Unlike most biomarkers on this site, there is no value in serial testing, no biological variability between draws, and no concept of trending over time. A single accurate test gives you a definitive answer. The only reason to retest would be if the original result was equivocal (typically from a flow cytometry method), in which case a confirmatory molecular test resolves the question.
What does change over time is what you do with the information. If you carry HLA-B27 and develop inflammatory symptoms, catching the diagnosis early matters. The average delay between symptom onset and diagnosis of axial spondyloarthritis is measured in years. People who know their HLA-B27 status and recognize the early signs of inflammatory back pain can get imaging and treatment sooner, potentially preventing the irreversible spinal fusion that characterizes advanced disease.
No medications, foods, exercise, illness, or time of day affect HLA-B27 DNA typing results. The test reads your genetic code, not a fluctuating protein or metabolite. The only sources of misleading results are methodological.
HLA-B27 DNA Typing is best interpreted alongside these tests.